Newscope Announces Name Change to PharmaTher Holdings Ltd.
TORONTO, April 13, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (the “Company”) (CSE: PHRM) (OTCQB: PHRRF) is pleased to announce that, further to the news release dated April 8, 2021, its common shares will commence trading through the facilities of the Canadian Securities Exchange (“CSE”) under the name of PharmaTher Holdings Ltd. at the start of trading on April 15, 2021.
The Company’s ticker symbols on both the CSE and the OTCQB® Venture Market will remain the same. The Company’s ISIN and CUSIP numbers for its common shares will change to CA71716H1082 and 71716H108, respectively.
No action is required to be taken by shareholders with respect to the name change. Outstanding share and warrant certificates are not affected by the name change and do not need to be exchanged.
About Newscope Capital Corporation
Newscope Capital Corporation is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals for FDA approval to treat neuropsychiatric, neurodegenerative and pain disorders.
Learn more at: PharmaTher.com and follow us on Twitter and LinkedIn. For more information, please contact:
Fabio Chianelli Chief Executive Officer Newscope Capital Corporation Tel: 1-888-846-3171 Email: [email protected] Website: www.pharmather.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
Source: Newscope Capital CorporationSerious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Build Heart-Healthy Habits That Last with 4 Simple, Everyday Steps
- New Vanderbilt Index Finds Sustainability Remains a Mainstream Consumer Priority
- Good Vibes Expands Access to Stem Cell Wellness With Financing and Personalized Care
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Twitter, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share